Dec 1, 2022
NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
(GEM21menos65) (Isatuximab-VRD + ASCT) - (VRD extended + ASCT plus ERI) - (Isatuximab-VID + ASCT). ERI=Early Rescue Intervention...
319
Dec 1, 2022
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma
NCT05218603: Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone...
90
Dec 1, 2021
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05060627: An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed...
146
Jun 23, 2021
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients NCT04802356: Phase 2:...
64
Dec 1, 2018
NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222: Phase 2: SELIBORDARA:...
35
Dec 1, 2017
NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma This is a multicenter, open label,...
68
Dec 19, 2015
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
GEM-CESAR trial PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...
464
Dec 3, 2015
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...
268
Dec 5, 2013
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
Phase III study PETHEMA (GEM2012MENOS65) GEM12 MENOS65 PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa...
313
Dec 14, 2007
NCT00461747: Phase 3 - GEM05 for Patients With Multiple Myeloma Under 65 Years (GEM05MENOS65)
GEM05 GEM05MENOS65 PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica...
318
Dec 7, 2007
NCT00480363: Phase 3: Revlimid / Dex ( ReDex) VS Observation in Smoldering MM (QUIREDEX)
QUIREDEX PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...
293